A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
HealthDay News — Benzodiazepine use in pregnancy is not associated with an increased risk for major congenital malformations, according to a study published online October 13 in the Annals of Internal ...
Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...
A new liquid formulation of cevimeline HCl offers a bioequivalent alternative for adult patients experiencing dry mouth ...
The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms and preventing postmenopausal ...
Strong recommendations made for semiannual surveillance for HCC, testing and vaccination for hepatitis A and B.
The newly approved autoinjector provides an alternative to the prefilled syringe for daily self-administration.
The application for the next-generation mitomycin formulation is supported by 3-month complete response data from the phase 3 UTOPIA trial.
Dostarlimab-gxly demonstrated high rates of sustained clinical complete response that allowed eligible patients to avoid chemotherapy, radiation, and surgery.
Researchers found that mean serum potassium was 4.16 and 4.18mmol/L in the group assigned DASH-patterned groceries and the self-directed group, respectively.
The Food and Drug Administration (FDA) has expanded the approval of Ryzumvi ® (phentolamine ophthalmic solution 0.75%) to include the treatment of presbyopia in adults.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results